We’re all aware of the biggest names in the cannabis industry right now. Companies like Canopy Growth, Aphria, Tilray, Cronos Group, and Aurora Cannabis are all mentioned when we see reports about “Market Leaders” in marijuana. The interesting part: there may be other businesses out there that could be built on a much more streamlined platform and could offer almost immediate access to the market potential ahead…
Building A Company Just Takes “Patients”
Canopy Growth reported 84,400 registered patients at September 30, 2016. In its latest financial report, Aurora Cannabis for example, reported that it had 67,484 active registered patients and this was up from roughly 43,000 during the prior quarter. Meanwhile you have funds like Vanguard Total Intl Stock Idx Fund, Golden Opportunities Diversified, Vanguard Developed Markets Index Fund, Vanguard FTSE All-Wld ex-US SmCp Idx Fd, iShares Core S&P/TSX Capped Compost ETF, and the two cannabis industry ETFs: Horizons Marijuana Life Sciences ETF & ETFMG Alternative Harvest ETF among others, holding more than a cumulative 40 million shares of Aurora in their portfolios (1).
But what if you found out that there’s another company out there that not only has over 100,000 patients (compared to Aurora’s less than 70,000) but also has built a diversified business model (like Aurora) targeting both the traditional healthcare market in addition to legal cannabis? Also, in comparison to Aurora’s $5.50+ per share price tag, the company I’m talking about is trading around 1/10th of that figure.
The company being discussed: Premier Health Group Inc., (OTC: PHGRF) (CSE: PHGI). Premier is developing innovative healthcare approaches that combine human skill based expertise with emerging technologies. Where the cannabis industry could come into play is with the company subsidiary HealthVue and its list of patients over 100,000 strong…that’s right…more than one hundred thousand ACTIVE patients.
Premier Health Group Inc., (OTC: PHGRF) (CSE: PHGI) has engaged discussions with Licensed Producers under the Access to Cannabis for Medical Purposes Regulation (ACMPR), other licensed medical cannabis companies and government officials in order to establish a framework for both patient and physician education. The company’s CEO said it perfectly:
“With over 110,000 active patients in our clinic ecosystem it is important that we provide them with the best possible information that allows them to make informed decisions about their personal and family’s health. Providing our family physicians with the appropriate tools and knowledge to prescribe cannabis or with the ability to refer patients to a specialist within our clinics is a key outcome of this initiative.”
-Dr. Essam Hamza , CEO of Premier Health Group Inc., (OTC: PHGRF) (CSE: PHGI)
Canadian Market Could Offer Opportunity For Premier Health Group Inc., (OTC: PHGRF) (CSE: PHGI).
1. The Canadian retail pharmacy market is estimated to be $44 billion (Source: IBISWorld). It is expected the industry sector will continue to allow for favorable economics for pharmacy operators as baby boomer’s demand increases for prescriptions and operators to expand the scope of practice to include preventative services.
2. The Canadian medical cannabis clinic market is estimated to be worth approximately $2.35 billion by 2025.
If these two facts weren’t enough, there is also a MAJOR Cross Over in Canada that connects medical cannabis & retail pharmacies. For some reason, news outlets aren’t paying attention to it right now either.
The crossover: Canadian pharmacies are fully behind medical marijuana too! Shoppers, Lovell Drugs and PharmaChoice have all signed supply deals with leading cannabis producers in Canada. Their pending entry into the medical cannabis market comes as the number of registered MMJ patients is soaring.
Premier Health Group Inc., (OTC: PHGRF) (CSE: PHGI) could have an ideal business model in progress that would vertically integrate cannabis as another growth opportunity. Also consider that industry peers like Aurora Cannabis don’t hold a flame to the number of active patients that Premier Health Group has and the numbers could really start to make a lot more sense once eyes begin to open on the street.
Again, just an opinion but when you compare the two, though Aurora is (finally) generating revenue, Premier Health is still in the early stages of growth yet already has access to a pool of patients that is more than 50% larger in size than Aurora and more than 15% to that of Canopy. It may all come down to timing of it all. As healthcare takes a center stage position during the latest bout of market volatility and cannabis legalization remains a focus of funds, looking for the next “star” to shine.
(1) As of Tue 27/11/2018 According to Morningstar http://quote.morningstar.ca/Quicktakes/owners/MajorShareholders.aspx?t=ACB®ion=CAN&culture=en-CA
DISCLAIMER: Pursuant to an agreement between MIDAM VENTURES, LLC and Premier Health Group Inc. we were hired for a period from 10/1/2018 – 4/1/2019 to publicly disseminate information about Premier Health Group Inc. including on the Website and other media including Facebook and Twitter. We were paid $300,000 ( CASH) for & were paid “500,000” shares of restricted common shares (as of 1/2/2019). We own zero shares of Premier Health Group Inc., which we purchased in the open market. Once the (6) Six-month restriction is complete on 4/1/2019 we plan to sell the “500,000” shares of Premier Health Group Inc. that we hold currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of Premier Health Group Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Click here for full disclaimer.
4 Security Penny Stocks To Watch
As Threats Arise, Security Stocks Take Center Stage In 2019
With the Federal Reserve’s meeting coming, the general market is bracing for anything. Meanwhile, penny stocks are continuing to climb at absurd rates. Trading penny stocks as of late has brought many investors fruitful profits and they look to continue this trend. Here are some security penny stocks to watch for the remainder of June 2019:
Security Penny Stock #1
Liberty Defense Holdings (SCAN.V)
Market Cap: $46.404M
Liberty Defense Holdings Ltd. (SCAN.V) is a security company looking to take the industry into the next century. Liberty’s HEXWAVE product is a 3-dimensional scanning device that can detect weapons and threats of any kind. The product can do this both with speed and discretion ensuring privacy for citizens.
Liberty signed a Memorandum of Understanding with the soccer team FC Bayern München to beta test HEXWAVE in their arena. They join an ever-growing list of places that have signed MOU’s to beta test Liberty’s product. This MOU expands its ability to comply with and test the market requirements for their product internationally.
“The reception to our HEXWAVE product has been fantastic and we are excited about working alongside FC Bayern Munich, a team that is a household name in both Europe and North America, […] Our ability to deploy in both indoor and outdoor settings, with covert and overt applications, sets us apart and has also been driving increasing interest from the market.”Bill Riker, CEO of Liberty
Security Penny Stock #2
Magal Security Systems (MAGS)
Market Cap: $101.371M
Magal Security Systems Ltd. (MAGS) provides security solutions both online and physical. Some services provided include identifying potential security problems, integrating new systems, and custom designs for any type of security needs.
Recently, Magal received a $5.5 million contract for its advanced perimeter intrusion detection system. The system prevents people from illegally crossing border fences and walls.
Dror Sharon, CEO of Magal, stated, “Magal is a world leader in perimeter intrusion technologies. Our growing wins of orders such as this – providing sensors for active international borders, is due to the decades of experience that we have in providing systems that have more than proven themselves in-the-field.”
Security Penny Stock #3
Rekor Systems (REKR)
Market Cap: $27.502M
Rekor Systems Inc. (REKR) is a company that has developed surveillance technology to enhance public safety, banking, and traffic management. Primarily, the company takes their advanced software, which utilizes machine learning and upgrades IP cameras to the next level. This reduces the cost when collecting highway tolls and helps manage traffic congestion.
Throughout June, Rekor Systems has been gaining recognition and application across the US. On June 3rd Rekor obtained a contract to start deploying its Mobile LBR-2 vehicle recognition systems. After this deployment on the 3rd, the LPR-2 system North Carolina law enforcement placed an order. On June 12th, Colorado highway authorities chose Rekor’s cloud system called NUMERUS to read enhance their license plate reading.
Security Penny Stock #4
BIO-key International (BKYI)
Market Cap: $18.03M
BIO-key International Inc. (BKYI) is a security technologies company that is pushing past the limits of fingerprint scanning. BIO-key provides a plethora of finger scanning products that provide security for your computer, hard drive, and the government. They have a partnership with Microsoft to develop biometric sign-in for Windows 10.
The company recently announced that a foreign defense ministry ordered more BIO-key deployment for secure access to Microsoft applications.
“We were delighted that such a capable and prestigious technology team determined that BIO-key met their security and scalability requirements and have now made follow-on investments to grow their user base. Defense Ministries are constant targets of cyber-attacks, and we are glad to help them step up authentication to the highest assurance with NIST-verified accuracy and FIPS compliance.”Jim Sullivan, SVP of BIO
Stock Price Pre Market Update – June 19, 2019
Big Investments Are Signaling The Green Light For A ‘Hot Market’ With Cancer-Fighting Stocks
How Tech Is Making Life Easier?
Healthcare Penny Stocks To Watch
Is Palatin Technologies (PTN) A Penny Stock To Buy Or Sell?
Is Palatin Technologies (PTN) A Penny Stock To Buy Or Sell?
Will Shares Of Palatin Technologies (PTN) Head Higher As Biotech Stocks Rally This Month?
Biotech stocks are rallying this month. Despite the “pop and drop” this sector saw earlier in the year, June has been a big month for biotechnology companies and people investing in this sector.
In fact, the iShares Trust Biotechnology ETF (IBB) has climbed by more than 8% since the start of June. This sector has been famous for producing volatile returns for investors. Furthermore, biotech penny stocks have increased that potential.
Palatin Technologies (PTN) Is A Biotech Penny Stock To Watch
One of the best performing penny stocks in the biotechnology sector this month has been Palatin Technologies Inc. (PTN). On January 2, this penny stock opened the year at $0.71 and has seen a 2019 high of $1.74. What’s more is that even though PTN stock has consolidated, it has continued to trade above $1.20.
So what’s all the excitement about? Palatin Technologies, Inc. is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential.
The company’s main strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential.
[New Research] Big Investments Are Signaling The Green Light For A ‘Hot Market’ With Cancer-Fighting Stocks
The recent excitement seems to have started in April after the company reported positive top-line results of its oral clinical study of PL-8177. The treatment is designed to address ulcerative colitis and other inflammatory bowel diseases.
“The main objective of the study was to demonstrate release of polymer-bound PL-8177 in the lower gastrointestinal tract after oral administration. Top line data showed favorable pharmacokinetics, and demonstrated PL-8177 was released in the lower gastrointestinal tract, supporting oral administration of PL-8177 using the delayed release polymer formulation.”
New Milestones From Palatine Technologies (PTN) Triggers New Highs
After hitting new highs on May 17th after posting quarterly earnings, shares of PTN stock have consolidated. Regardless, the company continues to progress. Earlier this month the company obtained orphan drug designation for PL-8177. Yes, this is the same one that I talked about above when the company received positive topline results earlier in the year.
Why is orphan drug designation important? This is a good question especially if you’re newer to biotech penny stocks or biopharmaceutical stocks, in general. In the exact words of the FDA:
“The Orphan Drug Act (ODA) provides for granting special status to a drug or biological product to treat a rare disease or condition upon request of a sponsor. This status is referred to as orphan designation (or sometimes “orphanstatus”).”
Essentially it gives companies incentives above and beyond competitors. These incentives include a partial tax credit for clinical trial expenditures, waived user fees, and eligibility for 7 years of marketing exclusivity. The obvious response would be favorable, which has been seen in the market over the past few trading sessions.
Dr. Carl Spana, President and Chief Executive Officer of Palatin Technologies, said in a press release, “Unlike corticosteroids, immunosuppressive agents, and biological therapies targeting specific cytokines or receptors, melanocortin receptor 1 peptides work to resolve chronic inflammations and restore normal immune function. We look forward to initiating clinical trials with PL-8177 for non-infectious uveitis, a high medical need disease with limited treatment options.”
But Here’s Why Palatin Might Be Set For More Excitement
It’s all about sex drive. You read that right. And something that hasn’t really been fully publicized is this “big FDA date.” You see on June 23rd, the application for Vyleesi (bremelanotide), a drug developed by Palatin and licensed to AMAG Pharmaceuticals (AMAG) will be up for review by the FDA as a New Drug.
Vyleesi is a novel melanocortin 4 receptor agonist under evaluation for restoring a natural sexual desire in premenopausal women with HSDD. Think of this like female Viagra. Will this become the sexiest biotech penny stock this month or will stock traders get blue balled?
Like This Article? Check Out: Small Cap Biotech Stocks See Boost From Large Cap M&A
Search Stock Price (StockPrice.com)
Sponsored Content4 days ago
Special Delivery! On-Demand Tech Companies Hit Billion-Dollar Valuations; Here’s How Investors Can Capitalize In The Market
Featured3 months ago
Multi-Trillion Dollar Industry Providing Massive Opportunity in 2019 & Beyond
Cannabis2 months ago
Two Massive Growth Industries, One Choice for Investors
Featured5 days ago
This New Technology Could Transform A Multi-Billion-Dollar Industry!
Biotechnology2 weeks ago
Big Investments Are Signaling The Green Light For A ‘Hot Market’ With Cancer-Fighting Stocks
Cannabis3 weeks ago
A New Cannabis Trend That The Market Should Take Immediate Notice Of Is Here!
Featured2 months ago
Opportunity Ahead for This Healthcare Stock
Stock Market Breaking News4 weeks ago
Liberty Defense (SCAN.V) Signs MOU with the Utah Attorney General for Testing of HEXWAVE